Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

TEM

Tempus AI Inc

Dec 30 • 04:00PM ET

60.39

-1.08 -1.76 %

Healthcare • Health Information Services • USA • NASD

Peers: ILMN EXAS GH TXG CRSP PACB NTLA EDIT CDNA TWST

| Held by: ARKK VTI VB VBK ARKG VXF BAI IBB IWP JTEK

Index	-	P/E	-	EPS (ttm)	-1.18	Insider Own	41.63%	Shs Outstand	172.63M	Perf Week	-8.39%
Market Cap	10.74B	Forward P/E	-	EPS next Y	-0.39	Insider Trans	-2.51%	Shs Float	103.84M	Perf Month	-22.51%
Enterprise Value	11.32B	PEG	-	EPS next Q	-0.04	Inst Own	47.34%	Short Float	17.44%	Perf Quarter	-25.18%
Income	-203.88M	P/S	9.72	EPS this Y	61.51%	Inst Trans	12.09%	Short Ratio	3.22	Perf Half Y	1.59%
Sales	1.11B	P/B	21.13	EPS next Y	35.41%	ROA	-12.53%	Short Interest	18.11M	Perf YTD	78.88%
Book/sh	2.86	P/C	14.14	EPS next 5Y	-	ROE	-72.61%	52W High	104.32 -42.11%	Perf Year	71.12%
Cash/sh	4.27	P/FCF	-	EPS past 3/5Y	-37.97% -32.48%	ROIC	-11.13%	52W Low	31.36 92.57%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	39.06% 38.58%	Gross Margin	60.33%	Volatility	3.42% 4.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	10.24	EPS Y/Y TTM	76.81%	Oper. Margin	-21.07%	ATR (14)	3.33	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.12	Sales Y/Y TTM	72.58%	Profit Margin	-18.45%	RSI (14)	29.84	Recom	1.88
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	0.15%	SMA20	-12.60%	Beta	5.10	Target Price	88.92
Payout	-	Debt/Eq	2.63	Sales Q/Q	84.72%	SMA50	-19.23%	Rel Volume	0.84	Prev Close	61.47
Employees	2400	LT Debt/Eq	2.61	Earnings	Nov 04 AMC	SMA200	-10.84%	Avg Volume	5.63M	Price	60.39
IPO	Jun 14, 2024	Option/Short	Yes / Yes	EPS/Sales Surpr.	36.16% 1.67%	Trades		Volume	4,733,956	Change	-1.76%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Morgan Stanley	Overweight	$85
Oct-21-25	Downgrade	TD Cowen	Buy → Hold	$88
Oct-20-25	Initiated	Canaccord Genuity	Buy	$110
Sep-02-25	Initiated	H.C. Wainwright	Buy	$90
Apr-21-25	Initiated	BTIG Research	Buy	$60
Feb-25-25	Downgrade	JP Morgan	Overweight → Neutral	$50 → $55
Feb-12-25	Downgrade	William Blair	Outperform → Mkt Perform
Feb-05-25	Resumed	TD Cowen	Buy	$58 → $74
Dec-13-24	Initiated	Wolfe Research	Outperform	$60
Dec-09-24	Initiated	Guggenheim	Buy	$74
Nov-11-24	Downgrade	Stifel	Buy → Hold	$45 → $65
Oct-02-24	Downgrade	BofA Securities	Buy → Neutral	$45 → $60
Aug-12-24	Initiated	Piper Sandler	Neutral	$40
Jul-09-24	Initiated	William Blair	Outperform
Jul-09-24	Initiated	TD Cowen	Buy	$50
Jul-09-24	Initiated	Stifel	Buy	$45
Jul-09-24	Initiated	Needham	Buy	$47
Jul-09-24	Initiated	Morgan Stanley	Overweight	$44
Jul-09-24	Initiated	Loop Capital	Buy	$48
Jul-09-24	Initiated	Longbow	Buy	$48

Show Previous Ratings

Today 07:32AM	How Tempus AI Is Building Scale While Near-Term Risks Persist (Zacks)
Dec-29-25 08:48AM	TEM vs. HIMS: Which Medical Info Systems Stock Offers Greater Upside (Zacks)
Dec-26-25 07:18AM	How Tempus AI Is Advancing Toward Regulatory Pricing Catch-Up (Zacks)
Dec-22-25 10:19PM	BofA and JPMorgan Lower Tempus AI, Inc. (TEM) Price Targets on Valuation Concerns (Insider Monkey)
09:53AM	JPMorgan Lowers Tempus AI (TEM) PT to $80, Maintains Neutral Rating (Insider Monkey)
07:36AM	Loading…
Dec-19-25 07:36AM	Tempus AI Approaching Profitability Despite GAAP Losses (Zacks)
Dec-17-25 11:22AM	Tempus AI Turns Non-GAAP Profit on Surging Genomics and Data (Zacks) -5.13%
Dec-16-25 12:11PM	Hims & Hers Scales Technology-Driven Care as Profitability Evolves (Zacks)
10:40AM	Tempus AI price target lowered to $80 from $90 at BofA (TipRanks)
09:07AM	Tempus AI Revenue Jumps 85% as Pricing Catalysts Line Up (Zacks)
08:13AM	3 MedTech Stocks Poised to Gain in 2026 From the AI Boom (Zacks)
Dec-15-25 11:30AM	Tempus AI Near $75 Target? Valuation, Upside and Risks (Zacks)
Dec-11-25 07:10AM	Tempus AI's Strategic Push to Expand Beyond Oncology (Zacks)
Dec-10-25 07:37AM	Is TEM Stock a Buy, Hold, or Sell During Its Pivotal Transition? (Zacks)
Dec-09-25 11:17AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
10:19AM	Loading…
10:19AM	Is Tempus AI Stock a Buy Now or a Hold After a Big 2025 Run? (Zacks)
08:30AM	Tempus Announces Ten Abstracts Accepted for Presentation at the 2025 San Antonio Breast Cancer Symposium (Business Wire)
Dec-08-25 02:08PM	5 Tech Stocks Insiders Are Selling (But Smart Investors Are Loading Up) (MarketBeat)
10:15AM	Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook (Zacks)
Dec-05-25 09:41AM	Tempus AI: Revenue Mix and 2026 Growth Outlook Explained (Zacks)
09:25AM	Is Tempus AI the Next Big Artificial Intelligence Stock to Buy? (Motley Fool)
08:44AM	Tempus AI Boosts Its Clinical AI Capabilities Through Strategic Moves (Zacks)
Dec-04-25 11:30AM	Why Is Tempus (TEM) Down 8.9% Since Last Earnings Report? (Zacks)
10:38AM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
Dec-01-25 05:28AM	Cathie Wood's Health Tech Bet: Why Analysts See Long-Term Upside in Tempus AI (TEM) (Insider Monkey)
Nov-28-25 03:18PM	Why Tempus AI Stock Soared This Week (Motley Fool)
Nov-25-25 12:28PM	Hims & Hers Expands Care Scope as Digital Health Platforms Evolve (Zacks)
07:46AM	Tempus AI's Data Business Is Expanding and Adding to Revenues: Here's How (Zacks)
Nov-24-25 07:53AM	TEM vs. BFLY: Which Stock Offers Greater Upside Amid Health Tech Boom? (Zacks) +8.21%
Nov-18-25 08:30AM	Tempus to Participate in the Piper Sandler 37th Annual Healthcare Conference (Business Wire)
08:55AM	Loading…
Nov-17-25 08:55AM	How Did Tempus AI Power Its Move to Positive EBITDA in Q3? (Zacks)
Nov-15-25 09:00AM	Alphabets Secret Portfolio Just Bought These 2 Stocks. Should You Buy Too? (24/7 Wall St.)
Nov-14-25 12:03PM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
08:30AM	Tempus and IFLI Announce Study to Advance Follicular Lymphoma Research (Business Wire)
07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks)
Nov-11-25 07:29AM	Should You Buy, Hold or Sell TEM Stock Post Q3 Earnings Release? (Zacks)
Nov-09-25 10:00PM	Nancy Pelosi posted up a staggering 16,930% return on investment, beat the market by 581%: Here are her 5 biggest wins (Moneywise)
Nov-07-25 12:43PM	Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care (Zacks)
10:15AM	Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought (Motley Fool)
Nov-06-25 01:22PM	Tempus AI: Volatility Equates to Opportunity in AI Leader (MarketBeat) -12.36%
Nov-05-25 11:01AM	TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours (Zacks)
08:30AM	Tempus Announces Six Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer Annual Meeting 2025 (Business Wire)
05:25AM	3 Growth Stocks to Invest $1,000 in Right Now (Motley Fool)
12:07AM	Tempus AI Inc (TEM) Q3 2025 Earnings Call Highlights: Strong Genomics Growth and Strategic ... (GuruFocus.com)
Nov-04-25 06:30PM	Tempus (TEM) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
05:45PM	Tempus AI (TEM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Tempus Reports Third Quarter 2025 Results (Business Wire)
06:01AM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)
Nov-03-25 04:36PM	Sex Dolls, Boycotts, Protests: Furor in France as Shein Opens Paris Store (The Wall Street Journal)
07:19AM	Tempus AI Inc (TEM) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-31-25 10:46AM	This AI Health Stock is Up Over 150% This Yearand Its Not Slowing Down (24/7 Wall St.)
Oct-30-25 07:45AM	Omnicell (OMCL) Q3 Earnings and Revenues Surpass Estimates (Zacks)
Oct-29-25 08:57AM	TEM vs. EXAS: Which Genomics Player Offers Greater Upside? (Zacks)
Oct-28-25 08:30AM	Tempus to Participate in the Stifel 2025 Healthcare Conference (Business Wire) -5.45%
05:53AM	Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine (Insider Monkey)
Oct-27-25 09:20AM	Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals (Zacks)
Oct-21-25 09:47AM	Tempus AI valuation catches up with its growth, says TD Cowen downgrading stock (Investing.com)
09:32AM	Goldman downgraded, Coinbase initiated: Wall Street's top analyst calls (The Fly)
08:30AM	Tempus to Report Third Quarter 2025 Financial Results on November 4 (Business Wire)
Oct-20-25 06:36PM	Why Tempus AI Stock Raced More Than 5% Higher Today (Motley Fool) +5.32%
04:56PM	These Stocks Moved the Most Today: Apple, Amazon, TSMC, Cleveland-Cliffs, Super Micro, Cooper Cos., Tesla, Netflix, and More (Barrons.com)
09:34AM	Apple upgraded, Rivian downgraded: Wall Street's top analyst calls (The Fly)
09:03AM	Tempus AI Stock Before Q3 Earnings Release: To Buy or Not to Buy? (Zacks)
09:00AM	Ambry Genetics Announces 10-Year Study in Genetics in Medicine Highlighting the Impact of Proactive Exome Reanalysis for Healthcare Equity (Business Wire)
Oct-17-25 09:45AM	Tempus AI Fuels Growth Through Strategic Biotech Collaborations (Zacks)
Oct-16-25 12:36PM	Hims & Hers Elevates Technology-Driven Healthcare Accessibility (Zacks)
08:30AM	Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research (Business Wire)
Oct-15-25 01:49PM	Tempus AI Hits $100-Are Shares Due for a Pullback? (MarketBeat)
08:30AM	Tempus Announces Six Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025 (Business Wire)
Oct-14-25 03:00PM	NVDA & PLTR Driving AI in Health: Top Health IT Stocks for Q3 Earnings (Zacks)
Oct-10-25 08:44AM	TEM Expands Partnership With Northwestern Medicine Amid AI Boom (Zacks)
Oct-09-25 10:54AM	Strategic Deals Drive TEM Growth Amid Competition: Buy, Hold or Sell? (Zacks)
08:30AM	Tempus Selected by ARPA-H to Provide CRO and Testing Services for the ADAPT Program, Advancing Precision Cancer Therapy (Business Wire)
Oct-08-25 05:48PM	These 5 Beaten-Down Tech Stocks Could Catch Fire Next (MarketBeat) +11.01%
11:22AM	Tempus AI, Inc. (TEM): A Bull Case Theory (Insider Monkey)
10:58AM	Breakthrough Discoveries Unlock $643B Cancer Treatment Market By 2034 (PR Newswire)
Oct-05-25 02:42AM	Tempus AI, Inc. (TEM) Secures FDA Clearance for xR IVD Device to Enhance Drug Discovery (Insider Monkey)
Oct-03-25 05:30AM	Why Tempus AI Stock Was Motoring Higher This Week (Motley Fool)
Oct-01-25 12:24PM	Ambry Genetics Announces Improved EHR-Integrated Breast Cancer Risk Assessment Solution with Upgraded Tyrer-Cuzick Scoring Approach Incorporating Breast Density (Business Wire) +9.02%
Sep-27-25 11:13AM	3 Healthcare Stocks Using AI to Drive Growth (MarketBeat)
08:45AM	What Are 2 Great Tech Stocks to Buy Right Now? (Motley Fool)
Sep-26-25 09:21AM	TEM vs. ILMN: Which Precision Oncology Stock Is Worth Buying Now? (Zacks)
Sep-25-25 06:53PM	Why Tempus AI Stock Is Plunging This Week (Motley Fool)
Sep-23-25 08:32AM	Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD (Zacks)
Sep-22-25 04:07PM	IBD 50's Tempus AI Pulls Back From Record High After Another FDA Clearance (Investor's Business Daily)
12:45PM	Hims & Hers Expands Care Ecosystem via Global and Digital Innovation (Zacks)
10:04AM	IBD 50's Tempus AI Hits Record High On Yet Another FDA Clearance (Investor's Business Daily)
09:00AM	3 Big Short Interest Names with Bullish Setups (MarketBeat)
08:30AM	Tempus Receives U.S. FDA 510(k) Clearance for Tempus xR IVD, its RNA NGS In Vitro Diagnostic Device (Business Wire)
Sep-21-25 09:30AM	Tempus AI Surges Since IPO as FDA Clearance Boosts Growth Outlook (Insider Monkey)
Sep-18-25 08:45AM	Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises (PR Newswire)
Sep-16-25 08:20AM	TEM Strengthens Radiology Portfolio With Pixel's FDA Clearance (Zacks)
Sep-15-25 08:00AM	Renalytix Announces Collaboration with Tempus to Advance Intelligent Risk Assessment in Diabetic Kidney Disease (PR Newswire)
Sep-12-25 09:42AM	Tempus AI (TEM) Touches 7-Month High on Pixel FDA Approval (Insider Monkey)
08:43AM	Tempus (TEM) Stock Jumps 13.6%: Will It Continue to Soar? (Zacks)
Sep-11-25 06:26PM	Why Tempus AI Stock Soared Nearly 14% Higher Today (Motley Fool) +13.59%
05:01PM	Northwestern Medicine Integrates Tempus AI's "David" Clinical Assistant into EHR Platform (Insider Monkey)
01:58PM	Tempus AI Gains FDA Clearance For Updated Pixel To Boost Accuracy And Efficiency In Cardiac Imaging (Benzinga)
11:11AM	Tempus AI Surges, Flirting With A Profit-Taking Zone, On A Fresh FDA Move (Investor's Business Daily)
08:35AM	TEM Gains Validation for PurIST Amid Evolving Cancer Care Landscape (Zacks)

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LEFKOFSKY ERIC P	CEO and Chairman	Dec 18 '25	Sale	63.99	166,250	10,638,478	8,974,783	Dec 22 05:41 PM
Eric Lefkofsky	Officer	Dec 18 '25	Proposed Sale	64.61	166,250	10,741,413		Dec 18 04:39 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Dec 16 '25	Sale	67.42	1,302	87,781	89,280	Dec 18 04:15 PM
ERIK PHELPS	Officer	Dec 16 '25	Proposed Sale	68.67	1,302	89,408		Dec 16 04:29 PM
Rogers James William	Chief Financial Officer	Dec 11 '25	Sale	73.20	19,966	1,461,479	111,250	Dec 12 04:30 PM
JAMES ROGERS	Officer	Dec 11 '25	Proposed Sale	75.07	19,966	1,498,848		Dec 11 04:23 PM
Frederick Wayne A.I.	Director	Dec 05 '25	Sale	77.23	3,675	283,820	24,836	Dec 09 04:15 PM
WAYNE FREDERICK	Director	Dec 05 '25	Proposed Sale	77.23	3,675	283,802		Dec 05 04:15 PM
Epstein David R	Director	Dec 01 '25	Sale	75.55	250	18,888	26,421	Dec 03 04:50 PM
Fukushima Ryan	Chief Operating Officer	Dec 01 '25	Sale	75.72	5,000	378,620	153,808	Dec 03 04:50 PM
Doudna Jennifer A	Director	Dec 01 '25	Sale	75.55	676	51,072	23,952	Dec 03 04:50 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 24 '25	Sale	74.10	166,250	12,319,125	9,008,033	Nov 25 04:30 PM
Polovin Andrew	EVP and General Counsel	Nov 24 '25	Sale	75.00	12,874	965,550	107,590	Nov 25 04:30 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	70.40	166,250	11,703,285		Nov 24 06:11 PM
ANDREW POLOVIN	Officer	Nov 24 '25	Proposed Sale	70.29	12,874	904,913		Nov 24 04:29 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 20 '25	Sale	68.97	166,250	11,466,099	9,041,283	Nov 20 07:56 PM
LEFKOFSKY ERIC P	CEO and Chairman	Nov 18 '25	Sale	65.54	16,829	1,102,944	2,003,213	Nov 20 07:56 PM
Rogers James William	Chief Financial Officer	Nov 18 '25	Sale	65.54	7,257	475,611	131,216	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 19 '25	Sale	68.06	6,387	434,707	120,464	Nov 20 07:05 PM
Polovin Andrew	EVP and General Counsel	Nov 18 '25	Sale	65.54	5,205	341,126	126,851	Nov 20 07:05 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Nov 18 '25	Sale	65.54	3,533	231,547	90,582	Nov 20 07:05 PM
Fukushima Ryan	Chief Operating Officer	Nov 18 '25	Sale	65.54	10,099	661,870	829,081	Nov 20 07:05 PM
Bartolucci Ryan M	Chief Accounting Officer	Nov 18 '25	Sale	65.54	1,834	120,197	44,061	Nov 20 07:05 PM
Eric Lefkofsky	Officer	Nov 20 '25	Proposed Sale	69.09	166,250	11,486,212		Nov 20 04:46 PM
ANDREW POLOVIN	Officer	Nov 19 '25	Proposed Sale	66.77	6,387	426,460		Nov 19 04:22 PM
Ryan M. Bartolucci	Officer	Nov 18 '25	Proposed Sale	66.39	1,834	121,759		Nov 18 07:09 PM
Ryan Fukushima	Officer	Nov 18 '25	Proposed Sale	66.39	10,099	670,473		Nov 18 07:08 PM
Eric Paul Lefkofsky	Officer	Nov 18 '25	Proposed Sale	66.39	16,829	1,117,277		Nov 18 07:07 PM
Andrew Polovin	Officer	Nov 18 '25	Proposed Sale	66.39	5,205	345,560		Nov 18 07:05 PM
James William Rogers	Officer	Nov 18 '25	Proposed Sale	66.39	7,257	481,792		Nov 18 07:04 PM
Erik Phelps	Officer	Nov 18 '25	Proposed Sale	66.39	3,533	234,556		Nov 18 07:03 PM
Doudna Jennifer A	Director	Nov 11 '25	Sale	71.45	1,926	137,613	24,628	Nov 13 04:15 PM
JENNIFER DOUDNA	Director	Nov 11 '25	Proposed Sale	71.78	3,852	276,497		Nov 12 07:03 AM
Fukushima Ryan	Chief Operating Officer	Nov 03 '25	Sale	89.03	5,000	445,160	125,000	Nov 05 04:15 PM
Epstein David R	Director	Nov 03 '25	Sale	90.00	370	33,300	26,671	Nov 05 04:15 PM
VANESSA L KUBO	Officer	Nov 03 '25	Proposed Sale	89.85	20,000	1,797,000		Nov 03 04:26 PM
DAVID R. EPSTEIN	Director	Nov 03 '25	Proposed Sale	89.85	990	88,952		Nov 03 04:25 PM
LEFKOFSKY ERIC P	CEO and Chairman	Oct 28 '25	Sale	89.11	332,500	29,629,006	9,074,532	Oct 30 04:31 PM
Eric Lefkofsky	Officer	Oct 28 '25	Proposed Sale	91.58	332,500	30,450,350		Oct 28 04:09 PM
Fukushima Ryan	Chief Operating Officer	Oct 06 '25	Sale	92.32	5,000	461,606	130,000	Oct 08 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Sep 25 '25	Sale	76.56	332,500	25,457,014	9,141,032	Sep 29 04:33 PM
Eric Lefkofsky	Officer	Sep 25 '25	Proposed Sale	84.13	332,500	27,973,225		Sep 25 07:04 PM
Fukushima Ryan	Chief Operating Officer	Sep 02 '25	Sale	75.80	10,000	758,028	135,000	Sep 04 04:15 PM
Epstein David R	Director	Sep 02 '25	Sale	73.64	250	18,410	27,041	Sep 04 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 27 '25	Sale	74.10	332,500	24,637,581	9,207,533	Aug 29 05:13 PM
Leonsis Theodore	Director	Aug 26 '25	Sale	75.83	20,000	1,516,600	66,756	Aug 28 04:15 PM
Eric Lefkofsky	Officer	Aug 27 '25	Proposed Sale	75.90	332,500	25,236,750		Aug 27 04:19 PM
Leonsis Theodore	Director	Aug 26 '25	Proposed Sale	75.83	20,000	1,516,650		Aug 26 01:27 PM
Polovin Andrew	EVP and General Counsel	Aug 19 '25	Sale	74.65	5,398	402,982	132,056	Aug 21 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Aug 19 '25	Sale	74.65	3,664	273,532	94,115	Aug 21 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Aug 19 '25	Sale	74.65	17,458	1,303,307	2,020,042	Aug 21 04:15 PM
Fukushima Ryan	Chief Operating Officer	Aug 19 '25	Sale	74.65	17,460	1,303,456	839,180	Aug 21 04:15 PM
Rogers James William	Chief Financial Officer	Aug 19 '25	Sale	74.65	7,528	561,994	138,473	Aug 21 04:15 PM
Bartolucci Ryan M	Chief Accounting Officer	Aug 19 '25	Sale	74.65	1,904	142,141	45,895	Aug 21 04:15 PM
Erik Phelps	Officer	Aug 19 '25	Proposed Sale	78.45	3,664	287,441		Aug 20 07:19 AM
Andrew Polovin	Officer	Aug 19 '25	Proposed Sale	78.45	5,398	423,473		Aug 20 07:17 AM
Ryan Fukushima	Officer	Aug 19 '25	Proposed Sale	78.45	17,460	1,369,737		Aug 20 07:15 AM
Eric Paul Lefkofsky	Officer	Aug 19 '25	Proposed Sale	78.45	17,458	1,369,580		Aug 20 07:14 AM
James William Rogers	Officer	Aug 19 '25	Proposed Sale	78.45	7,528	590,572		Aug 19 09:59 PM
Ryan M. Bartolucci	Officer	Aug 19 '25	Proposed Sale	78.45	1,904	149,369		Aug 19 09:56 PM
Leonsis Theodore	Director	Aug 13 '25	Proposed Sale	69.90	44,000	3,075,786		Aug 18 02:44 PM
Leonsis Theodore	Director	Aug 13 '25	Sale	69.90	44,000	3,075,600	86,756	Aug 15 09:21 PM
Epstein David R	Director	Aug 01 '25	Sale	55.16	370	20,409	27,291	Aug 05 04:15 PM
DAVID R. EPSTEIN	Director	Aug 01 '25	Proposed Sale	56.59	620	35,086		Aug 01 04:30 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jul 28 '25	Sale	62.87	166,250	10,452,027	9,274,033	Jul 30 08:42 PM
Eric Lefkofsky	Officer	Jul 28 '25	Proposed Sale	64.49	166,250	10,721,462		Jul 28 04:13 PM
Fukushima Ryan	Chief Operating Officer	Jul 07 '25	Sale	60.00	5,000	300,000	145,000	Jul 09 04:15 PM
VANESSA L KUBO	Officer	Jul 07 '25	Proposed Sale	60.97	20,000	1,219,400		Jul 07 04:16 PM
Doudna Jennifer A	Director	Jul 01 '25	Sale	62.52	625	39,075	26,554	Jul 03 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 17 '25	Sale	70.07	250,000	17,516,593	9,357,283	Jun 20 04:15 PM
LEFKOFSKY ERIC P	CEO and Chairman	Jun 18 '25	Sale	69.44	250,000	17,359,469	9,307,283	Jun 20 04:15 PM
Phelps Erik	EVP & Chief Admin & Legal Off	Jun 16 '25	Sale	72.56	51,317	3,723,634	97,779	Jun 18 04:15 PM
Polovin Andrew	EVP and General Counsel	Jun 16 '25	Sale	72.13	1,423	102,641	137,454	Jun 18 04:15 PM
Eric Paul Lefkofsky	Officer	Jun 17 '25	Proposed Sale	72.00	400,000	28,800,000		Jun 17 09:45 PM
ERIK PHELPS	Officer	Jun 16 '25	Proposed Sale	71.28	51,317	3,657,876		Jun 16 04:30 PM
ANDREW POLOVIN	Officer	Jun 16 '25	Proposed Sale	71.28	1,423	101,431		Jun 16 04:22 PM
Leonsis Theodore	Director	Jun 11 '25	Sale	67.66	205,847	13,927,976	0	Jun 13 04:15 PM
Revolution Growth Management C	Shareholder	Jun 11 '25	Proposed Sale	69.38	205,847	14,281,665		Jun 11 04:02 PM
Fukushima Ryan	Chief Operating Officer	Jun 03 '25	Sale	62.29	20,000	1,245,764	856,640	Jun 05 04:15 PM
Doudna Jennifer A	Director	Jun 02 '25	Sale	55.20	558	30,802	27,179	Jun 04 04:15 PM
Epstein David R	Director	Jun 02 '25	Sale	55.20	250	13,800	27,661	Jun 04 04:15 PM
JENNIFER A DOUDNA	Director	Jun 02 '25	Proposed Sale	55.18	1,183	65,278		Jun 02 04:32 PM
Rogers James William	Chief Financial Officer	May 20 '25	Sale	63.27	23,121	1,462,809	146,001	May 22 08:00 PM
Polovin Andrew	EVP and General Counsel	May 20 '25	Sale	63.43	17,552	1,113,385	138,877	May 22 08:00 PM
Phelps Erik	EVP & Chief Admin & Legal Off	May 20 '25	Sale	63.21	8,415	531,918	149,096	May 22 08:00 PM
LEFKOFSKY ERIC P	CEO and Chairman	May 20 '25	Sale	63.21	16,752	1,058,905	4,878,837	May 22 08:00 PM
Fukushima Ryan	Chief Operating Officer	May 20 '25	Sale	63.21	7,820	494,308	876,640	May 22 08:00 PM
Bartolucci Ryan M	Chief Accounting Officer	May 20 '25	Sale	63.23	6,073	384,023	47,799	May 22 08:00 PM
Ryan M. Bartolucci	Officer	May 20 '25	Proposed Sale	63.74	4,254	271,150		May 21 07:39 PM
Ryan Fukushima	Officer	May 20 '25	Proposed Sale	63.74	7,820	498,447		May 21 07:36 PM
Andrew Polovin	Officer	May 20 '25	Proposed Sale	63.74	9,797	624,461		May 21 07:25 PM
Eric Paul Lefkofsky	Officer	May 20 '25	Proposed Sale	63.74	16,752	1,067,772		May 21 07:23 PM
Erik Phelps	Officer	May 20 '25	Proposed Sale	63.74	8,415	536,372		May 21 07:20 PM
James William Rogers	Officer	May 20 '25	Proposed Sale	63.74	11,413	727,465		May 21 07:18 PM
RYAN BARTOLUCCI	Officer	May 20 '25	Proposed Sale	63.74	1,819	115,943		May 20 04:32 PM
ANDREW POLOVIN	Officer	May 20 '25	Proposed Sale	63.74	7,755	494,304		May 20 04:31 PM
JAMES ROGERS	Officer	May 20 '25	Proposed Sale	63.74	11,708	746,268		May 20 04:31 PM
Leonsis Theodore	Director	May 09 '25	Sale	66.26	770	51,020	43,550	May 13 04:15 PM
REVOLUTION GROWTH III, LP	Shareholder	May 09 '25	Proposed Sale	65.22	770	50,219		May 09 04:18 PM
Fukushima Ryan	Chief Operating Officer	May 06 '25	Sale	52.36	20,000	1,047,239	884,460	May 08 04:30 PM

Open in Screener

PFE

Pfizer Inc

Dec 30 • 04:00PM ET

24.99

-0.01 -0.04 %

Healthcare • Drug Manufacturers - General • USA • NYSE

Peers: BMY MRK SNY AMGN ABBV NVS JNJ GSK LLY AZN

| Held by: VTI VOO IVV SPY VTV XLV VYM VHT DVY FDL

Index	S&P 500	P/E	14.57	EPS (ttm)	1.72	Insider Own	0.09%	Shs Outstand	5.69B	Perf Week	-0.87%
Market Cap	142.09B	Forward P/E	8.35	EPS next Y	2.99	Insider Trans	0.00%	Shs Float	5.68B	Perf Month	-2.91%
Enterprise Value	189.11B	PEG	-	EPS next Q	0.58	Inst Own	66.89%	Short Float	2.46%	Perf Quarter	-1.92%
Income	9.80B	P/S	2.26	EPS this Y	0.45%	Inst Trans	-0.28%	Short Ratio	2.04	Perf Half Y	-0.20%
Sales	62.78B	P/B	1.53	EPS next Y	-4.25%	ROA	4.58%	Short Interest	139.49M	Perf YTD	-5.80%
Book/sh	16.32	P/C	9.48	EPS next 5Y	-2.59%	ROE	10.59%	52W High	27.69 -9.75%	Perf Year	-5.91%
Cash/sh	2.64	P/FCF	13.69	EPS past 3/5Y	-28.69% -13.27%	ROIC	6.52%	52W Low	20.92 19.48%	Perf 3Y	-51.61%
Dividend Est.	1.70 (6.81%)	EV/EBITDA	7.23	Sales past 3/5Y	-7.84% 9.10%	Gross Margin	69.12%	Volatility	1.04% 1.97%	Perf 5Y	-31.98%
Dividend TTM	1.72 (6.88%)	EV/Sales	3.01	EPS Y/Y TTM	128.96%	Oper. Margin	30.99%	ATR (14)	0.48	Perf 10Y	-18.76%
Dividend Ex-Date	Jan 23, 2026	Quick Ratio	0.97	Sales Y/Y TTM	4.44%	Profit Margin	15.60%	RSI (14)	45.64	Recom	2.39
Dividend Gr. 3/5Y	2.49% 2.97%	Current Ratio	1.28	EPS Q/Q	-20.96%	SMA20	-1.69%	Beta	0.43	Target Price	28.51
Payout	120.11%	Debt/Eq	0.66	Sales Q/Q	-5.92%	SMA50	-0.56%	Rel Volume	0.42	Prev Close	25.00
Employees	81000	LT Debt/Eq	0.62	Earnings	Nov 04 BMO	SMA200	2.04%	Avg Volume	68.50M	Price	24.99
IPO	Jan 17, 1944	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.53% 0.94%	Trades		Volume	28,741,562	Change	-0.04%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-02-25	Resumed	Citigroup	Neutral	$26
Nov-13-25	Initiated	Scotiabank	Sector Outperform	$30
Apr-22-25	Initiated	Cantor Fitzgerald	Neutral	$24
Dec-10-24	Resumed	BofA Securities	Neutral	$29
Nov-15-24	Initiated	Wolfe Research	Underperform	$25
Oct-25-24	Resumed	Citigroup	Neutral	$30
Oct-17-24	Initiated	Bernstein	Mkt Perform	$32
Aug-07-24	Upgrade	Daiwa Securities	Neutral → Outperform
Mar-22-24	Downgrade	Argus	Buy → Hold
Feb-23-24	Initiated	Guggenheim	Buy	$36
Jan-04-24	Downgrade	TD Cowen	Outperform → Market Perform	$32
Oct-20-23	Resumed	UBS	Neutral	$36 → $34
Oct-16-23	Upgrade	Jefferies	Hold → Buy	$38 → $39
Jul-17-23	Reiterated	JP Morgan	Neutral	$45 → $41
Jul-14-23	Initiated	HSBC Securities	Buy	$50
Jun-29-23	Downgrade	Credit Suisse	Outperform → Neutral	$47 → $40
May-11-23	Downgrade	Daiwa Securities	Outperform → Neutral	$38
Mar-06-23	Initiated	Jefferies	Hold	$43
Feb-07-23	Upgrade	Daiwa Securities	Neutral → Outperform	$51
Jan-26-23	Downgrade	UBS	Buy → Neutral	$55 → $47

Show Previous Ratings

Today 06:02PM	Pfizer (PFE) Braces for Bumpy Years as Growth Pushed Out to 2029 (Insider Monkey)
01:22PM	BMY vs AMGN: Which Biotech Stock Is More Resilient Now? (Zacks)
04:11AM	Want $300 in Super-Safe Dividend Income in 2026? Invest $2,670 Into the Following 3 Ultra-High-Yield Stocks. (Motley Fool)
Dec-29-25 11:59PM	Here's What Analysts Think About Pfizer Inc. (PFE) (Insider Monkey)
12:35PM	Jim Cramer Names His Favorite Dividend Stocks (24/7 Wall St.)
09:35PM	Loading…
Dec-28-25 09:35PM	The Smartest Dividend Stocks to Buy With $3,000 Right Now (Motley Fool)
Dec-27-25 04:48PM	3 Drug Stocks to Buy at a Discount (Motley Fool)
06:50AM	3 Superb High-Yield Dividend Stocks With Yields North of 5% That Make for No-Brainer Buys Right Now (Motley Fool)
02:30AM	This Beaten-Down Pharma Stock Could Make a Turnaround in the New Year (Barrons.com)
Dec-26-25 11:07AM	This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131% (Investor's Business Daily)
09:12AM	Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath? (Zacks)
09:00AM	Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It (Zacks)
08:21AM	Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth? (Zacks)
Dec-25-25 09:00AM	As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock? (Barchart)
03:11AM	BofA Trims Pfizer (PFE) PT as COVID-19 Sales Slide and Obesity Focus Shifts to Metsera (Insider Monkey)
11:20AM	Loading…
Dec-24-25 11:20AM	PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth (Zacks)
Dec-23-25 05:45PM	Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
02:09PM	Will the Recent Pricing Deal With the Government Impact BMY's Sales? (Zacks)
11:15AM	Pfizer Stock Is Down -- Patient Death in Hemophilia Study Raises Safety Concerns (GuruFocus.com)
Dec-22-25 01:43PM	Bet on These Top-Ranked Healthcare ETFs Before 2025 Ends (Zacks)
08:19AM	This Pharma Stock Had a Rough Year. Why One Analyst Thinks It Can Rise 250%. (Barrons.com)
03:58AM	Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead? (Motley Fool)
Dec-21-25 10:07AM	Jim Cramer on Pfizer: "I'm Going to Say Just Weak Hold" (Insider Monkey)
Dec-20-25 07:00AM	MarketBeat Week in Review - 12/15 - 12/19 (MarketBeat)
Dec-19-25 05:40PM	Dow Jones' Merck, Other Drugmakers Strike Drug-Pricing Bargains With Trump (Investor's Business Daily)
04:30PM	Nine Drugmakers Strike Deals With Trump, With More to Come (Bloomberg)
04:07PM	Lilly Shares Have Tripled on Weight-Loss Drugs. Why the Stock Looks Cheap. (Barrons.com)
03:20PM	Better Buy in 2026: Pfizer or Merck? (Motley Fool)
03:14PM	White House Cuts Drug-Pricing Deals With Pharma Companies, Tilting System Toward Self-Pay (Barrons.com)
12:15PM	Pharma's $370B Bet on America: The ETF Plays for 2026 (Zacks)
11:42AM	Loading…
11:42AM	White House Will Announce Pricing Deals With More Drugmakers Friday (Barrons.com)
10:46AM	Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock (Zacks)
09:51AM	Pfizer (PFE) CEO's Struggling Because Of "a Good Hand," Says Jim Cramer (Insider Monkey)
06:01AM	Novo files for CagriSema approval; Merck and Pfizers trial win (BioPharma Dive)
Dec-18-25 08:50PM	3 Absurdly Cheap Stocks You Can Buy For Less than $100 Right Now (Motley Fool)
12:05PM	Better Buy in 2026: Pfizer or Eli Lilly? (Motley Fool)
10:40AM	3 Cancer Stocks to Buy Amid Rapid Advances in Cancer Treatment (Zacks)
10:00AM	Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts (Business Wire)
05:30AM	JPMorgan Quants Warn of Extreme Crowding in Speculative Stocks (Bloomberg)
Dec-17-25 08:09PM	Lightning Round: I would buy M&T Bank tomorrow morning, says Jim Cramer (CNBC TV)
05:08PM	Pfizer Inc (PFE) Rating Steady Amid Neutral Market Outlook and Pipeline Progress (Insider Monkey)
12:07PM	If I Could Only Buy and Hold a Single Stock, This Would Be It (Motley Fool)
11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
09:59AM	Pfizer Issues Soft 2026 View: What Does It Mean for the Stock's Future? (Zacks)
09:51AM	Company News for Dec 17, 2025 (Zacks)
08:35AM	The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now (Motley Fool)
06:45AM	PADCEV Plus Keytruda Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility (PR Newswire)
06:19AM	S&P Futures Gain as Investors Weigh U.S. Jobs Data, Fed Speak and Micron Earnings in Focus (Barchart)
Dec-16-25 05:50PM	Analyst Report: Pfizer Inc. (Morningstar Research)
05:45PM	Pfizer (PFE) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
04:33PM	Stocks Settle Mixed on Soft US Economic News (Barchart)
04:24PM	Stock Market Today: Dow Slides, Nasdaq Positive After Jobs Data; Nvidia Rises (Live Coverage) (Investor's Business Daily)
04:22PM	Why Pfizer's 2026 Guidance Miss Is 'Not A Major Surprise' (Investor's Business Daily)
04:21PM	Monte Rosa Scores A Win In Prostate Cancer, And Rockets To A Four-Year High (Investor's Business Daily)
04:18PM	These Stocks Moved the Most Today: Tesla, Pfizer, Humana, Circle, CoreWeave, Broadcom, IonQ, Ford, Navan, and More (Barrons.com)
04:03PM	Tepid 2026 outlook dents Pfizer shares (AFP)
03:37PM	Pfizer outlook, Humana leadership shake-up, Kraft Heinz's new CEO (Yahoo Finance Video)
02:14PM	These Stocks Are Moving the Most Today: Tesla, Pfizer, Humana, Circle, CoreWeave, Broadcom, IonQ, Ford, Navan, and More (Barrons.com)
02:08PM	Stock Market Today: Dow Drops After Mixed Jobs Data; Cannabis Stocks Soar (Live Coverage) (Investor's Business Daily)
01:39PM	Pfizer trims 2026 profit forecast amid Covid headwinds and patent cliff pressures (Pharmaceutical Technology)
01:08PM	Energy and healthcare stocks are dragging the market lower on Tuesday (MarketWatch)
01:04PM	Pfizer falls on disappointing guidance (CNBC TV)
12:07PM	Pfizer CEO Defends Vaccines, Promises Growth by End of Decade (Barrons.com)
11:36AM	Why Pfizer (PFE) Stock Is Sliding Today (GuruFocus.com)
11:10AM	Pfizer Sees 2026 Profit Below Estimates as COVID Sales Decline (GuruFocus.com)
09:40AM	Kraft Heinz taps new CEO, PayPal files for US bank charter (Yahoo Finance Video)
07:47AM	Here's why Pfizer is revising its revenue forecasts (MarketWatch)
07:25AM	Pfizer Stock Edges Higher on 2026 Guidance. Expect a Rough Year for Covid Vaccine Sales. (Barrons.com)
07:16AM	Pfizer Expects Decline in Covid-19 Drug Demand to Hurt 2026 Earnings (The Wall Street Journal)
07:03AM	Pfizer Adds to Its Big Bet on Weight Loss Drugs (MarketBeat)
06:45AM	Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance (Business Wire)
05:35AM	Where Will Eli Lilly Be in 10 Years? (Motley Fool)
Dec-15-25 09:32AM	BMY Gains 13.1% in Three Months: Buy, Sell or Hold the Stock? (Zacks)
09:00AM	Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know (Zacks)
09:00AM	GeoVax Announces British Journal of Haematology Publication Highlighting Superior T-Cell Responses of GEO-CM04S1 in CLL Patients (NewMediaWire)
Dec-14-25 03:47PM	Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? (Motley Fool)
Dec-13-25 07:13AM	Forget Teladoc and Buy This Healthcare Stock Instead (Motley Fool)
Dec-12-25 12:00PM	Pfizer Declares First-Quarter 2026 Dividend (Business Wire)
11:52AM	Pfizer Is Still Struggling to Replace Its COVID Revenue. Here's What We Could See From the Pharmaceutical Giant in 2026. (Motley Fool)
11:17AM	Eli Lilly's Next-Generation Obesity Drug Secures First Phase III Win (Zacks)
10:35AM	The Best Turnaround Stock to Invest $1,000 in Right Now (Motley Fool)
Dec-11-25 02:03PM	Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.? (GuruFocus.com)
10:57AM	CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? (Zacks)
10:09AM	Pfizer plans job cuts in Switzerland to reduce expenses (Pharmaceutical Technology)
07:49AM	Here's How AbbVie's Oncology Drugs are Aiding Top-line Growth (Zacks)
07:32AM	Pfizer Inc. (PFE) Announces Results from Phase 3 BASIS Study (Insider Monkey)
03:45AM	Ex-Pfizer executive joins Elevances board as insurer pursues pharmacy experience (Healthcare Dive)
Dec-10-25 05:45PM	Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider (Zacks)
04:35PM	Warning: This Skyrocketing Stock Has a Hidden Risk (Motley Fool)
11:47AM	This Invesco ETF Pays a 4.71% Yield With 50 Low-Volatility Dividend Stocks (3x the S&P 500) (24/7 Wall St.)
11:28AM	Pfizer Inc. (PFE) Announces Results from the Phase 3 BASIS Study Evaluating HYMPAVZI (Insider Monkey)
08:15AM	TUKYSA Added to First-Line Maintenance Therapy Extends Median Progression-Free Survival by Over 8 Months in Patients with HER2+ Metastatic Breast Cancer (Business Wire)
07:43AM	PFE Buys Oral GLP-1 Drug From China Biotech to Boost Obesity Presence (Zacks)
07:31AM	JNJ vs. PFE: Which Blue-Chip Drug Stock is the Better Investment Now? (Zacks)
06:26AM	The Fed's Divided on Rates. Why Stock Markets Can Rise Through 2026 Anyway and 5 Other Things to Know Today. (Barrons.com)
04:30AM	China's Fosun Pharma unit strikes US$2.1 billion obesity drug deal with Pfizer (South China Morning Post)
Dec-09-25 04:35PM	Down 50%, Should You Buy the Dip on Pfizer? (Motley Fool)
04:13PM	In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera? (Investor's Business Daily)
01:40PM	Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal (Zacks)
12:30PM	Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill (GuruFocus.com)

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Dolsten Mikael	Former Officer	May 23 '25	Proposed Sale	23.09	59,781	1,380,632		May 23 10:54 AM
Dolsten Mikael	Former Officer	May 05 '25	Proposed Sale	23.87	55,000	1,312,736		May 05 04:45 PM
DAMICO JENNIFER B.	SVP & Controller	Mar 04 '25	Sale	25.93	2,500	64,825	11,850	Mar 06 01:57 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 27 '25	Option Exercise	31.31	22,416	701,845	31,063	Mar 03 05:39 PM
SUSMAN SALLY	Executive Vice President	Feb 27 '25	Option Exercise	31.31	85,182	2,667,048	250,866	Mar 03 05:38 PM
SAHNI PAYAL	Executive Vice President	Feb 27 '25	Option Exercise	31.31	19,054	596,581	44,242	Mar 03 05:38 PM
McDermott Michael	Executive Vice President	Feb 27 '25	Option Exercise	31.31	48,419	1,515,999	122,413	Mar 03 05:37 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 27 '25	Option Exercise	31.31	156,914	4,912,977	309,790	Mar 03 05:37 PM
Fonseca Lidia	Executive Vice President	Feb 27 '25	Option Exercise	31.31	72,629	2,274,014	111,534	Mar 03 05:36 PM
BOURLA ALBERT	Chairman & CEO	Feb 27 '25	Option Exercise	31.31	582,823	18,248,188	931,744	Mar 03 05:36 PM
McDermott Michael	Executive Vice President	Feb 22 '25	Option Exercise	30.17	11,125	335,641	87,636	Feb 25 07:38 PM
DAMICO JENNIFER B.	SVP & Controller	Feb 22 '25	Option Exercise	30.17	8,741	263,716	17,602	Feb 25 07:38 PM
BOURLA ALBERT	Chairman & CEO	Feb 22 '25	Option Exercise	30.17	238,399	7,192,498	570,436	Feb 25 07:06 PM
LANKLER DOUGLAS M	Executive Vice President	Feb 22 '25	Option Exercise	30.17	85,824	2,589,310	232,775	Feb 25 07:05 PM
SAHNI PAYAL	Executive Vice President	Feb 22 '25	Option Exercise	30.17	12,714	383,581	37,099	Feb 25 07:04 PM
SUSMAN SALLY	Executive Vice President	Feb 22 '25	Option Exercise	30.17	63,573	1,917,997	225,184	Feb 25 07:02 PM
BOSHOFF CHRISTOFFEL	President, R&D	Feb 22 '25	Option Exercise	30.17	8,741	263,716	159,085	Feb 25 06:58 PM
BLAYLOCK RONALD E	Director	Feb 13 '25	Buy	25.65	19,457	499,072	27,707	Feb 14 05:16 PM

TEM

Tempus AI Inc

PFE

Pfizer Inc

Upgrade your FINVIZ experience